COMMENTARY

Neural Diseases: Inhibitors of p38 MAP Kinase as Potential Therapeutic Agents

Wesley Davies*

NEURAL DISEASES

Various cellular stressors, as well as inflammatory cytokines, activate mammalian p38 Mitogen-Activated Protein Kinases (MAPKs). Activation of the p38 MAPK pathway is a critical stage in the development of various disorders in the Central Nervous System (CNS), and the molecular processes mediated by p38 MAPK signaling have been identified. When this cascade is activated, pro-inflammatory cytokines are released, which have been linked to cerebral ischemia, Alzheimer's Disease (AD), Parkinson's Disease (PD), Multiple Sclerosis (MS), neuropathic pain, and depression. In Alzheimer's disease, activated p38 MAPK may cause hyperphosphorylation of tau, a brain microtubule-associated protein. Furthermore, we recently discovered that activating p38 MAPK signaling reduces dendritic spine quantity, which may be related to memory impairment following epileptic episodes. As a result, p38 MAPK can be used as a target for new medication development for neurological disorders. p38 MAPK inhibitors have been widely investigated in both preclinical and clinical studies for inflammatory disorders. In phase II clinical studies for neuropathic pain and depression, new p38 MAPK inhibitors are being explored. In this paper, we look at the present and potential future uses of p38 MAPK inhibitors as therapeutic agents in neurological disorders.

Mitogen-Activated Protein Kinases (MAPKs) are a group of molecules that have evolved over time and play important roles in cell signaling and gene regulation. Extracellular Signal-Regulated Kinase (ERK), p38 MAPK, and c-Jun N-Terminal Kinase (JNK) are three main members of the MAPK family that are engaged in three distinct signaling cascades. Phosphorylation activates MAPKs, which then transduce a wide range of extracellular inputs into various intracellular responses via transcriptional and non transcriptional regulation.

p38 MAPK is a stress-induced kinase that plays an important role in inflammatory reactions. It has been demonstrated that the p38 MAPK inhibitor efficiently relieves rheumatoid arthritis and inflammatory pain. p38 MAPK is strongly expressed in areas of the Central Nervous System (CNS) that are important for learning and memory, and it is likely a critical component in higher brain processes. Furthermore, activation of this pathway may be linked to the development of some neurological disorders such as Alzheimer's Disease (AD), ischemia, neuropathic pain, epilepsy, and depression. The activation of p38 MAPK has also been discovered to reduce the number of dendritic spines, which may be associated with learning and memory deficits following epileptic episodes. As a result, p38 MAPK is a viable therapeutic target. As a result, p38 MAPK is a viable target for therapeutic development in the treatment of neurodegenerative disorders.

Since the discovery of the first archetypal p38 inhibitor, SB203580, in 1994, other p38 inhibitors have been produced. Several p38 inhibitors have been studied in vivo using animal models of brain illnesses, and these medicines have been found to be useful in treating various neural disease symptoms. In this vein, p38 inhibitors are seen as promising prospective treatment medicines for various neurological disorders. First, we'll talk about the p38 MAPK pathway in the brain. The investigation of the p38 MAPK pathway may give new insights into the mechanisms of various neurological diseases.

We have discussed p38 MAPK and neurological disorders in this article. Multiple lines of evidence show that p38 MAPK inhibitors are useful tools for understanding the basic underpinnings of such illnesses. It has progressively been discovered, in particular, that activation of p38 MAPK induces dendritic spine loss in various neurological disorders, and that this spine loss may be accompanied by the memory impairment seen in epilepsy and dementia. Despite the fact that p38 MAPK is a viable therapeutic target for brain disorders, few particular inhibitors have been used in clinical trials due to their significant adverse effects. Future research focused on defining the role of p38 MAPK in brain disorders may aid in defining this enzyme's possible relevance in the pathogenesis of particular neural diseases. Given the vast spectrum of pathophysiological conditions in which p38 MAPK is abnormally active, its signaling pathway is a viable target for research into innovative treatment methods targeted at alleviating p38 activation in a number of brain disorders.

Editorial Office, Journal of Clinical Diagnosis and Treatment, Windsor Berkshire, United Kingdom

Correspondence: Wesley D, Editorial Office, Journal of Clinical Diagnosis and Treatment, Windsor Berkshire, United Kingdom, E-mail: davieswly..@gmail.com

Received: March 03, 2021, Accepted: March 17, 2021, Published: March 24, 2021